

## Review

**Cite this article:** Maléth J, Hegyi P. 2016 $\text{Ca}^{2+}$  toxicity and mitochondrial damage in acute pancreatitis: translational overview. *Phil. Trans. R. Soc. B* **371**: 20150425.<http://dx.doi.org/10.1098/rstb.2015.0425>

Accepted: 30 March 2016

One contribution of 15 to a Theo Murphy meeting issue 'Evolution brings  $\text{Ca}^{2+}$  and ATP together to control life and death'.**Subject Areas:**

health and disease and epidemiology

**Keywords:**acute pancreatitis, mitochondrial damage,  $\text{Ca}^{2+}$  overload**Author for correspondence:**

Péter Hegyi


e-mail: [hegyi.peter@pte.hu](mailto:hegyi.peter@pte.hu); [p.hegyi@tm-pte.org](mailto:p.hegyi@tm-pte.org)[tm-pte.org](http://tm-pte.org) $\text{Ca}^{2+}$  toxicity and mitochondrial damage in acute pancreatitis: translational overviewJózsef Maléth<sup>1,2</sup> and Péter Hegyi<sup>1,2,3</sup><sup>1</sup>First Department of Medicine, and <sup>2</sup>MTA-SZTE Momentum Translational Gastroenterology Research Group, University of Szeged, Szeged, Hungary<sup>3</sup>Institute for Translational Medicine, University of Pécs, Pécs, Hungary

Acute pancreatitis (AP) is a leading cause of hospitalization among non-malignant gastrointestinal disorders. The mortality of severe AP can reach 30–50%, which is most probably owing to the lack of specific treatment. Therefore, AP is a major healthcare problem, which urges researchers to identify novel drug targets. Studies from the last decades highlighted that the toxic cellular  $\text{Ca}^{2+}$  overload and mitochondrial damage are key pathogenic steps in the disease development affecting both acinar and ductal cell functions. Moreover, recent observations showed that modifying the cellular  $\text{Ca}^{2+}$  signalling might be beneficial in AP. The inhibition of  $\text{Ca}^{2+}$  release from the endoplasmic reticulum or the activity of plasma membrane  $\text{Ca}^{2+}$  influx channels decreased the severity of AP in experimental models. Similarly, inhibition of mitochondrial permeability transition pore (MPTP) opening also seems to improve the outcome of AP in *in vivo* animal models. At the moment MPTP blockers are under detailed clinical investigation to test whether interventions in MPTP openings and/or  $\text{Ca}^{2+}$  homeostasis of the cells can be specific targets in prevention or treatment of cell damage in AP.

This article is part of the themed issue 'Evolution brings  $\text{Ca}^{2+}$  and ATP together to control life and death'.

1.  $\text{Ca}^{2+}$  is controlling secretory events in pancreatic acinar and ductal cells

Intracellular  $\text{Ca}^{2+}$  signalling plays central role in the regulation of the secretory processes of the exocrine pancreas. It is a well-known fact that in the exocrine pancreas acinar cells secrete digestive enzymes and pancreatic ductal epithelial cells secrete  $\text{HCO}_3^-$  rich alkaline fluid that washes the digestive enzymes out from the pancreas. The prompt coordination of the secretory events of the two cell types is essential and  $\text{Ca}^{2+}$  has a central role in both pancreatic physiology and pathophysiology. Recent studies suggest that these two cell types cannot be handled separately since they are more likely integrated into a functional unit [1]. This is further amplified by the neurohormonal regulation of exocrine pancreatic secretion. It has been demonstrated that acetylcholine (the main stimulatory neurotransmitter of the pancreas) is released from the parasympathic nerve endings, releasing digestive enzymes from the acinar cells [2], whereas at the same time enhances the pancreatic ductal fluid and  $\text{HCO}_3^-$  secretion via  $\text{M}_3$  metabotropic cholinergic receptor ( $\text{M}_3\text{R}$ ) mediated  $\text{Ca}^{2+}$  release [3]. In addition, the circulating hormone cholecystokinin (CCK) regulates pancreatic secretion via oscillatory  $\text{Ca}^{2+}$  signals [4]. In pancreatic ductal epithelial cells (PDECs), the role of CCK stimulation differs between species, in humans it has negligible direct effects, but remarkably potentiates the stimulatory effect of secretin on the  $\text{HCO}_3^-$  secretion [5]. The proper control of secretion is further potentiated by the strong synergy between  $\text{Ca}^{2+}$  and cAMP signalling [6]. The physiological roles of



**Figure 1.** Hypothetical sequence of events in the pathogenesis of AP. Pancreatitis inducing toxic stress factors can release the intracellular  $Ca^{2+}$  from the stores, such as the endoplasmic reticulum (ER), or acidic organelles. However, the constant presence of toxins will lead to the elongation of the  $Ca^{2+}$  signals via multiple mechanisms. First, the ER  $Ca^{2+}$  depletion activates the influx of extracellular (EC)  $Ca^{2+}$ . Second, the direct mitochondrial toxicity of the stress factors (such as bile acids or non-oxidative ethanol metabolites), increases reactive oxygen species production and the sustained  $Ca^{2+}$  increase will lead to the opening of the MPTP that will damage the mitochondria. The lack of intracellular ATP impairs the function of  $Ca^{2+}$  extrusion and reuptake pumps such as PMCA or SERCA. These changes together will generate a vicious cycle leading to inhibited secretion and intracellular activation of digestive enzymes in acinar cells and impaired ductal fluid and  $HCO_3^-$  secretion. Altogether, these changes will trigger cell necrosis and AP.

$Ca^{2+}$  signalling in epithelial secretion have been outlined in more detail in excellent reviews [7–10].

## 2. The price of versatility: $Ca^{2+}$ toxicity in acute pancreatitis

Although it is well established that physiological  $Ca^{2+}$  signalling controls the normal pancreatic functions on multiple levels, it is also well documented that uncontrolled cellular  $Ca^{2+}$  overload leads to cellular damage and pathogenesis of acute pancreatitis (AP; figure 1). In this chapter, we will summarize the effects of the common stress factors that cause AP.

### (a) Bile acids

Biliary pancreatitis is one of the most common forms of AP, although the exact pathogenesis is not known in detail. One possible explanation is the ‘common channel’ theory, which suggests that an impacted gallstone creates communication behind the stone connecting the common bile duct to the pancreatic duct. This would theoretically allow bile acids (BAs) to reach the pancreatic ductal lumen or even the acinar cells [11]. However, this hypothesis was questioned by several studies suggesting that instead of the reflux mechanism, increased luminal pressure would cause the pancreatic damage [12–15]. Whether or not BAs reach the pancreatic tissue directly from the luminal side, several observations suggest that BA reaching the ductal cells from either basolateral or luminal sides can trigger multiple cellular responses in acinar and ductal cells that might contribute to the development of AP.

Earlier, our group showed that the hydrophobic, non-conjugated BA, chenodeoxycholate (CDCA) dose-dependently affects  $HCO_3^-$  secretion of pancreatic ductal epithelia [16]. We found that lower concentration of CDCA (100  $\mu$ M) stimulated and high concentration (1 mM) severely inhibited the

ion transport activities including the ductal  $HCO_3^-$  secretion. The explanation for this dual effect might be the type of  $Ca^{2+}$  signals triggered by CDCA. Luminal administration of 100  $\mu$ M CDCA evoked short oscillatory  $Ca^{2+}$  signals, which were fully abolished by  $IP_3$  receptor inhibition. On the other hand, challenging the pancreatic ductal cells with 1 mM CDCA caused a sustained  $Ca^{2+}$  elevation [16] and severe damage of the mitochondrial morphology and function [17]. Interestingly, in our hands N,N'-[1,2-ethanediybis(oxy-2,1-phenylene)]bis[N-2-[(acetyloxy)methoxy]-2-oxoethyl]-bis[(acetyloxy)methyl]ester (BAPTA-AM) failed to prevent the mitochondrial damage and therefore the inhibitory effect of CDCA on the  $HCO_3^-$  secretion [16], which might be explained by the existence of a  $Ca^{2+}$ -independent direct mitochondrial toxicity of bile acids [18]. Similarly to ductal cells, pancreatic acinar cells respond with intracellular  $Ca^{2+}$  elevation to BA challenge [19] due to  $IP_3R$  and ryanodine receptor activation. It is also well documented that tauroolithocholic acid 3-sulfate diminishes cellular ATP production [20] and dissipate the mitochondrial membrane potential ( $\Delta\Psi_m$ ), which was not affected by BAPTA-AM treatment [21]. Although BA directly affects the acinar cells, the observations of Perides *et al.* actually suggest that biliary pancreatitis is a receptor mediated disease [22]. They showed that the G-protein-coupled cell surface bile acid receptor (Gpbar1, or TGR5) is expressed at the apical membrane of pancreatic acinar cells and its activation is associated with pathological  $Ca^{2+}$  signals, intracellular activation of digestive enzymes and cell injury, i.e. the hallmarks of AP. Whereas the genetic deletion of Gpbar1 markedly reduced the severity of tauroolithocholic acid 3-sulfate (TLCS)-induced, but not caerulein-induced AP. Very recently, Katona *et al.* provided solid evidence that specific BA might be used as treatment option against biliary pancreatitis [23]. They showed that pre-treatment of pancreatic ducts with ursodeoxycholate (UDCA) remarkably ameliorated the toxic effects of UDCA. Chenodeoxycholate-induced intracellular

ATP depletion, mitochondrial injury, and as a consequence, cell death were completely prevented by UDCA, whereas the activity of the epithelial acid–base transporters was preserved in *in vitro* experiments. In addition, *in vivo* experiments showed that oral administration of UDCA significantly reduced the severity of CDCA-induced AP. Interestingly, UDCA had no effect on the sustained  $\text{Ca}^{2+}$  elevation triggered by CDCA, raising the possibility of a direct mitochondrial protective effect, which is yet to be determined. These observations nicely supplement the previous results of Seyhun *et al.*, who showed that the endoplasmic reticulum (ER) chaperone tauroursodeoxycholic acid inhibits the unfolded protein response (UPR) *in vitro* [24] and *in vivo* [25]. This effect reduced the activation of UPR components and reduced intracellular trypsin activation, oedema formation and cell damage in pancreatic acinar cells.

### (b) Ethanol and non-oxidative ethanol metabolites

The second most frequent form of pancreatitis is alcohol-induced AP [26]. Whereas genetic factors seem to be involved in the disease development [27], several studies investigated the direct effects of ethanol and different ethanol metabolites on the exocrine pancreas. Ethanol and its oxidative metabolite acetaldehyde have moderate effects on the  $[\text{Ca}^{2+}]_i$  in pancreatic acinar cells even in extremely high concentrations [28]. Whereas the non-oxidative ethanol metabolites (fatty acid ethyl esters, FAEE) induced sustained  $[\text{Ca}^{2+}]_i$  elevation and a drop of cellular ATP leading to necrosis [28–30]. Importantly, the breakdown of FAEE to fatty acids (FA) by intracellular hydrolases significantly contribute to the toxic effects of non-oxidative ethanol metabolites [30]. This fact has been further emphasized in a recent elegant study by Huang *et al.* [31]. They showed that the inhibition of oxidative ethanol metabolism significantly enhance, whereas inhibition of non-oxidative ethanol metabolism augment pancreatic damage in an *in vivo* model of ethanol-fatty acid induced AP. On the other hand pancreatic ductal cells respond to low to high concentrations of alcohol, likewise to BA. Yamamoto *et al.* showed that 1 mM ethanol induces  $[\text{Ca}^{2+}]_i$  elevation and augments fluid secretion, whereas high concentration moderately inhibits the stimulated fluid secretion in secretin-stimulated guinea pig pancreatic ducts [32]. Our group recently investigated the effects of ethanol and ethanol metabolites in more detail [33]. We showed that alcohol and fatty acids inhibit fluid and  $\text{HCO}_3^-$  secretion, as well as cystic fibrosis transmembrane conductance regulator (CFTR) activity, in pancreatic ductal cells. Interestingly, in the case of FAEE only the inhibition of the CFTR channel was observed in high concentrations [34]; however, the inhibition of  $\text{HCO}_3^-$  secretion was not observed [33]. The remarkable inhibitory effects of alcohol and fatty acids were mediated by sustained increase of intracellular  $\text{Ca}^{2+}$ , inhibited adenosine 3',5'-cyclic monophosphate and ATP production and depolarization of  $\Delta\Psi_m$ . We also showed that ethanol reduced expression of CFTR via multiple pathways, which in turn augmented the severity of experimental alcohol-induced AP in mice.

### (c) Other stress factors

As demonstrated above, the two most common pathogenic factors of AP—BA and ethanol—damage the exocrine pancreas via  $\text{Ca}^{2+}$  toxicity and mitochondrial injury. Notably, these cellular changes seem to be the key of AP pathogenesis since a considerable number of studies showed that other stress

factors provoke the same alterations in  $\text{Ca}^{2+}$  signalling and energy metabolism. Intrapancreatic trypsinogen activation is a hallmark of AP pathogenesis and we showed earlier that trypsin acting via PAR2 on the luminal membrane induces intracellular  $\text{Ca}^{2+}$  elevation and inhibits the luminal acid/base transporters in PDEC [35]. Moreover, the inhibitory effect was abolished by BAPTA-AM preincubation, similarly to the inhibitory effects of ethanol and fatty acids. Very recently, Jin *et al.* investigated the pathomechanism of an iatrogen form of AP, the post-ERCP pancreatitis [36]. Using sophisticated *in vitro* and *in vivo* models, they showed that exposure of pancreatic acinar cells to iohexol (a radiocontrast agent) triggered sustained intracellular  $\text{Ca}^{2+}$  elevation. The downstream activation of NF- $\kappa$ B and NFAT is completely abolished by the suppression of the  $\text{Ca}^{2+}$  signals. Moreover, they proved that the downstream effects of  $\text{Ca}^{2+}$  were mediated by calcineurin since genetic, or pharmacological inhibition of calcineurin prevented the radiocontrast-induced damage. This interesting study further underlines the central role of pathophysiological  $\text{Ca}^{2+}$  signalling in the pathogenesis of AP regardless of the etiological factor.

## 3. Sources of $\text{Ca}^{2+}$ in pancreatic acinar and ductal cells

### (a) $\text{Ca}^{2+}$ release from the endoplasmic reticulum

Agonist binding (Ach, ATP) to G-protein-coupled receptors activate phospholipase C  $\beta$  (PLC $\beta$ ) in pancreatic acinar and ductal cells. The activated PLC $\beta$  releases inositol trisphosphate ( $\text{IP}_3$ ) by hydrolysing phosphatidylinositol 4,5-bisphosphate ( $\text{PIP}_2$ ) [37]. Under physiological conditions, the intracellular  $\text{Ca}^{2+}$  signals have a strict spatio-temporal localization [38,39], mostly limiting  $\text{Ca}^{2+}$  signals to the apical pole of the cells. As in other non-excitable cell types, this is ensured by two ATP-dependent pumps that clear the cytosol from the free  $\text{Ca}^{2+}$ . The sarco/endoplasmic reticulum  $\text{Ca}^{2+}$ -ATPase (SERCA) pumps and the plasma membrane  $\text{Ca}^{2+}$ -ATPase (PMCA) pumps move  $\text{Ca}^{2+}$  from the cytosol to the ER and the extracellular space, respectively. This activity restores basal intracellular  $\text{Ca}^{2+}$  levels and refills the ER  $\text{Ca}^{2+}$  stores. In PDEC, the  $\text{Ca}^{2+}$  signalling is not characterized in such detail; however, the overall polarity of the ductal cells including the ion channels and transporters,  $\text{IP}_3$  receptors and mitochondria [17], suggest a very similarly regulated  $\text{Ca}^{2+}$  signalling, like in acinar cells. Further studies are required for the clarification of these questions.

### (b) Extracellular $\text{Ca}^{2+}$ influx

The complex role of extracellular  $\text{Ca}^{2+}$  influx to orchestrate non-excitable cell functions has been established several decades ago [40]; however, the molecular components participating in the process remained unknown until 2005. Hoth *et al.* found that agonist-mediated depletion of the intracellular  $\text{Ca}^{2+}$  stores induced a  $\text{Ca}^{2+}$  selective sustained inwardly rectifying current, which was termed  $I_{\text{CRAC}}$  (calcium release-activated calcium current) [41]. The real revolution of the field began by the discovery of the ER  $\text{Ca}^{2+}$  sensor stromal interaction molecule 1 (Stim1) [42] and the plasma membrane  $\text{Ca}^{2+}$  channel Orai1 [43,44]. Briefly, the process of store operated  $\text{Ca}^{2+}$  entry (SOCE) consist of the following elements. In resting conditions the ER  $\text{Ca}^{2+}$  stores are refilled and Stim1 distributes in the ER membrane. However during physiological stimulation the ER  $\text{Ca}^{2+}$  stores are quickly depleted, which induces the dissociation of the bound  $\text{Ca}^{2+}$

from the EF hand of Stim1. This is followed by a conformational change and translocation of Stim1 to defined ER-PM junctions, termed as puncta formation [45]. This translocation is required for the activation of the plasma membrane  $\text{Ca}^{2+}$  influx channel Orai1, where the Stim Orai1-activating region (SOAR) and polybasic domains of Stim1 interact with different binding sites of Orai1 that results in clustering and activation of the channel [46]. In addition to Orai1, other possible  $\text{Ca}^{2+}$  entry channels that seem to play a role in Stim1-mediated SOCE are the TRPC channels [47,48]. These channels function as  $\text{Ca}^{2+}$ -permeable non-selective cation channels mediating receptor evoked  $\text{Ca}^{2+}$  influx in many cells [49]. SOCE have been investigated mostly in acinar cells of various exocrine glands, as models of polarized epithelial cells [50–52]. Interestingly, the role of SOCE in the physiological functions of PDEC, especially in  $\text{HCO}_3^-$  secretion remained elusive. Kim *et al.* found that intracellular  $\text{Ca}^{2+}$  elevation, caused by the activation of SOCE might play a role in exocytosis in pancreatic ductal cells isolated from dog main pancreatic duct [53,54]; however, they did not investigate  $\text{HCO}_3^-$  secretion of PDEC, which therefore needs further investigation.

#### 4. Mitochondrial $\text{Ca}^{2+}$ handling and $\text{Ca}^{2+}$ overload of mitochondria


During physiological  $\text{Ca}^{2+}$  signalling, mitochondria takes up  $\text{Ca}^{2+}$ , which has been shown to directly increase energy output by enhancing the activity of tricarboxylic acid cycle dehydrogenases and the ATP synthase [55]. The pioneer work of Rizzuto *et al.* highlighted that the cytosolic  $\text{Ca}^{2+}$  signals propagate to the mitochondria [56] and a couple of years later Csordas *et al.* found that ER membrane and the outer mitochondrial membrane form a quasi-synaptic connection [57] that is the structural bases of the  $\text{Ca}^{2+}$  hotspots [58]. Despite the functional characterization of the mitochondrial  $\text{Ca}^{2+}$  signalling the molecular background of the process was not known. In 2011, two groups independently identified the mitochondrial  $\text{Ca}^{2+}$  uniporter (MCU), an inner mitochondrial membrane protein that is responsible for the mitochondrial  $\text{Ca}^{2+}$  uptake [59,60]. The  $\text{Ca}^{2+}$  efflux from the mitochondria is mediated by the mitochondrial  $\text{Na}^+/\text{Ca}^{2+}$  exchanger (NCLX) [61], thus the mitochondrial  $\text{Ca}^{2+}$  level is tightly regulated under physiological conditions. However, pathophysiological signals can lead mitochondrial injury, which can activate both apoptosis and necrosis. The classical mitochondrial apoptotic pathway involves the outer membrane permeabilization by Bax and Bak (two members of the pro-death Bcl-2 family) that will allow apoptotic factors like cytochrome *c*, Smac/DIABLO and apoptosis inducing factor to be released from the intermembrane space into the cytosol, leading to cell death by apoptosis [62]. On the other hand,  $\text{Ca}^{2+}$  overload or increased reactive oxygen species (ROS) production can cause the opening of mitochondrial permeability transition pore (MPTP) that results in the loss of mitochondrial inner membrane potential, uncoupling of the respiratory chain with a consequent drop of mitochondrial ATP synthesis, and increased permeability of the inner mitochondrial membrane that eventually leads to mitochondrial swelling, rupture and necrotic cell death [63,64]. Notably, recent studies lead to the reconsideration of the role of MPTP in cellular physiology, since it has been proved to be important in several physiological processes such as energy metabolism [65], mitochondrial  $\text{Ca}^{2+}$  efflux [66] and ROS signalling [67] as well. The molecular

identity of MPTP is still a matter of investigation [68]. The historical model of MPTP included the voltage-dependent anion channel (VDAC) in the outer mitochondrial membrane, the adenine nucleotide translocator (ANT) in the inner mitochondrial membrane, and CypD as its regulator in the matrix of the mitochondria [69]. However recent intensive efforts revealed new molecules that might contribute to the MPTP formation (reviewed in detail [68,70]). A growing number of evidence suggest that VDAC is not very likely to contribute to the MPTP formation. On the other hand, studies on ANT suggest that it is not required for MPTP formation, but it regulates MPTP activity [71]. CypD is an important regulator of MPTP as supported by genetically modified mice [72] and pharmacologic inhibition of CypD by cyclosporine A [73]. On the other hand, several studies suggested that the activity of  $\text{F}_1\text{F}_0$  ATP synthase or the proapoptotic Bax/Bak proteins [74] are required for proper MPTP function [75], whereas other proteins, such as mitochondrial phosphate carrier, might impact the pore opening indirectly [76]. At the moment the role of MPTP in the pathogenesis of AP is supported by limited, but still solid evidence. Mukherjee *et al.* demonstrated that both genetic and pharmacologic inhibition of MPTP opening (using the Cyclophilin D-deficient *Ppif* gene knockout mice, or *in vivo* treatment with cyclosporine A derivatives, respectively) significantly ameliorated pancreatic damage in different experimental AP models in mice [77]. Importantly MPTP blockade protected the pancreatic acinar cells from necrosis whereas apoptosis was not affected, which is in strong agreement of earlier studies [72].

#### 5. Novel therapeutic targets in acute pancreatitis

In pancreatic acinar cells,  $\text{IP}_3$ -mediated  $\text{Ca}^{2+}$  release from the ER is an essential component of the physiological response to agonist stimulation, but it could also contribute to the pathological  $\text{Ca}^{2+}$  overload of the cells evoked by toxic factors that induce AP (cerluin hyperstimulation, bile acids, or ethanol and ethanol metabolites) [39]. Caffeine is a known inhibitor of  $\text{IP}_3$ Rs due to multiple actions that include the inhibition of phospholipase C-mediated production of  $\text{IP}_3$  [78], antagonism of  $\text{IP}_3$ Rs [79] and direct binding to  $\text{IP}_3$ Rs that reduce the channels open-state probability [80]. Interestingly, coffee consumption moderately reduces the risk of alcohol-associated pancreatitis suggesting that the inhibitory effect of caffeine on  $\text{IP}_3$ -mediated  $\text{Ca}^{2+}$  signalling may be protective in AP [81]. Based on these considerations Huang *et al.* recently studied the effects of caffeine and its xanthine metabolites on pancreatic acinar  $\text{IP}_3$ R-mediated  $\text{Ca}^{2+}$  signalling and experimental AP [82]. They found that caffeine and dimethylxanthines (but not monomethylxanthines) blocks  $\text{IP}_3$ -mediated  $\text{Ca}^{2+}$  oscillations in response to uncaged  $\text{IP}_3$  or toxins, prevented mitochondrial depolarization and necrotic cell death *in vitro* and significantly impaired the severity of experimental AP in three different models. These observations suggest that caffeine, or its metabolites might be suitable starting points to develop therapy for AP (figure 2).

As discussed above, store operated  $\text{Ca}^{2+}$  entry could be a key component in the development of cellular  $\text{Ca}^{2+}$  overload. Earlier Kim *et al.* showed that genetic [83] or pharmacological inhibition (using the TRPC3-specific inhibitor pyrazole 3) [84] of TRPC3 significantly reduce the sustained  $\text{Ca}^{2+}$  elevation in pancreatic acinar cells evoked by cell stressors (bile acid or fatty acid ethyl ester). In addition, it prevented the pathological



**Figure 2.** Novel therapeutic targets in AP. Experimental studies from recent years identified several proteins in cellular  $\text{Ca}^{2+}$  signaling machinery that might be potential target molecules in AP treatment. Caffeine and dimethyl-xanthenes were shown to block  $\text{IP}_3$ -mediated  $\text{Ca}^{2+}$  release from the ER that decreased the severity of AP in experimental models. Similarly, the inhibition of the plasma membrane  $\text{Ca}^{2+}$  influx channels Orai1 and TRPC3 reduced the severity of AP in animal models. Another treatment possibility might be the inhibition of the MPTP opening, which improved the disease outcome in rodents.

inhibition of digestive enzyme secretion and markedly reduced intracellular trypsin activation and excessive actin depolymerization *in vitro* and the severity of pancreatitis *in vivo*. Recently, Gerasimenko *et al.* demonstrated the pharmacological inhibition of another  $\text{Ca}^{2+}$  entry channel Orai1 by a specific inhibitor called GSK-7975A which prevents acinar cell necrosis *in vitro* [85]. This important observation was supported by Wen *et al.*, who tested the effects of two specific Orai1 inhibitors (GSK-7975A and CM\_128) in isolated human and rodent pancreatic acinar cells and in different experimental AP models [86]. They showed that both Orai1 inhibitors prevented the sustained  $\text{Ca}^{2+}$  elevation *in vitro* and significantly impaired signs of pancreatic injury including pancreatic oedema, inflammation and necrosis in all tested experimental models.

Mitochondrial permeability transition is a key feature of cellular damage in many cell types and diseases (see above); therefore, MPTP blockers are under detailed clinical investigation in different studies. In a recent clinical study, the efficacy and safety of TRO40303 (an MPTP inhibitor) have been evaluated for the reduction of reperfusion injury in

patients undergoing revascularization for ST-elevation myocardial infarction (MITOCARE study) [87]. This study did not show any effect of TRO40303 in limiting reperfusion injury of the ischaemic myocardium. In another recently completed CIRCUS trial, the effects of i.v. administrated cyclosporine have been evaluated on the clinical outcome of patients with anterior STEMI [88]. Similarly to the MITOCARE study, CIRCUS trial did not report any improvement in the cyclosporine-treated patients. The reasons for the failure of the studies might be explained by pharmacological limitations of the administrated compounds [89] that include low tissue penetration due to the lack of collateral blood flow and high metabolism of the compound in the blood. In addition, MPTP blockers have been suggested to be beneficial in hepatitis C therapy, since they inhibited hepatitis C virus (HCV) replication by preventing a cyclophilin-A induced cis-trans isomerization in domain II of NS5A [90]. However, it was not investigated in clinical trials further. Very recently, Mukherjee *et al.* tested the effect of MPTP inhibition on the severity of AP in rodent experimental AP models [77]. They have shown that the inhibition of MPTP with pharmacological compounds (two cyclosporine A derivate: DEB025 or TRO40303), or genetic deletion of the *Ppif* gene (that encodes cyclophilin D, a component of MPTP) significantly decreases the severity of AP in different independent models. These observations suggest that the MPTP inhibition might be potentially beneficial in the AP therapy. Other indirect evidence for this hypothesis has been provided by Judak *et al.*, who showed that the supplementation of cellular ATP *in vitro* diminished the inhibitory effect of ethanol metabolites on the ion transport activities in isolated guinea pig pancreatic ductal cells [34]. These results suggest that the restoration of the cellular energy level can be beneficial in AP, which can prevent the cellular dysfunction and cell damage.

## 6. Closing remarks

Although there are several promising results and potential drug targets that play a role in the pathogenesis of AP, it remains a great challenge for researchers and clinicians. A number of unanswered questions are waiting for answers. Moreover, it will take several years to test the experimental results on clinical patients as well. To be able take up these challenges, clinicians and researchers should work closely together in the future.

**Competing interests.** We declare we have no competing interests.

**Funding.** Our research was supported by the Hungarian Scientific Research Fund (PD115974 (J.M.), K116634 (P.H.)) and the Momentum grant of the Hungarian Academy of Sciences (LP2014-10/2014 (P.H.)).

## References

- Maleth J, Hegyi P. 2014 Calcium signaling in pancreatic ductal epithelial cells: an old friend and a nasty enemy. *Cell Calcium* **55**, 337–345. (doi:10.1016/j.ceca.2014.02.004)
- Matthews EK, Petersen OH, Williams JA. 1973 Pancreatic acinar cells: acetylcholine-induced membrane depolarization, calcium efflux and amylase release. *J. Physiol.* **234**, 689–701. (doi:10.1113/jphysiol.1973.sp010367)
- Hootman SR, Zukerman J, Kovalcik SA. 1993 Muscarinic receptors in isolated guinea pig pancreatic ducts. *Biochem. Pharmacol.* **46**, 291–296. (doi:10.1016/0006-2952(93)90417-U)
- Murphy JA *et al.* 2008 Direct activation of cytosolic  $\text{Ca}^{2+}$  signaling and enzyme secretion by cholecystokinin in human pancreatic acinar cells. *Gastroenterology* **135**, 632–641. (doi:10.1053/j.gastro.2008.05.026)

5. You CH, Rominger JM, Chey WY. 1983 Potentiation effect of cholecystokinin-octapeptide on pancreatic bicarbonate secretion stimulated by a physiologic dose of secretin in humans. *Gastroenterology* **85**, 40–45.
6. Ahuja M, Jha A, Maleth J, Park S, Muallem S. 2014 cAMP and Ca<sup>2+</sup>(+) signaling in secretory epithelia: crosstalk and synergism. *Cell Calcium* **55**, 385–393. (doi:10.1016/j.ceca.2014.01.006)
7. Petersen OH. 2014 Calcium signalling and secretory epithelia. *Cell Calcium* **55**, 282–289. (doi:10.1016/j.ceca.2014.01.003)
8. Jung J, Lee MG. 2014 Role of calcium signaling in epithelial bicarbonate secretion. *Cell Calcium* **55**, 376–384. (doi:10.1016/j.ceca.2014.02.002)
9. Gerasimenko J, Peng S, Gerasimenko O. 2014 Role of acidic stores in secretory epithelia. *Cell Calcium* **55**, 346–354. (doi:10.1016/j.ceca.2014.04.002)
10. Lee MG, Ohana E, Park HW, Yang D, Muallem S. 2012 Molecular mechanism of pancreatic and salivary gland fluid and HCO<sub>3</sub> secretion. *Physiol. Rev.* **92**, 39–74. (doi:10.1152/physrev.00011.2011)
11. Lerch MM, Aghdassi AA. 2010 The role of bile acids in gallstone-induced pancreatitis. *Gastroenterology* **138**, 429–433. (doi:10.1053/j.gastro.2009.12.012)
12. Lerch MM, Saluja AK, Runzi M, Dawra R, Saluja M, Steer ML. 1993 Pancreatic duct obstruction triggers acute necrotizing pancreatitis in the opossum. *Gastroenterology* **104**, 853–861.
13. Menguy RB, Hallenbeck GA, Bollman JL, Grindlay JH. 1958 Intraductal pressures and sphincteric resistance in canine pancreatic and biliary ducts after various stimuli. *Surg. Gynecol. Obstet.* **106**, 306–320.
14. DiMagno EP, Shorter RG, Taylor WF, Go VL. 1982 Relationships between pancreaticobiliary ductal anatomy and pancreatic ductal and parenchymal histology. *Cancer* **49**, 361–368. (doi:10.1002/1097-0142(19820115)49:2<361::AID-CNCR2820490225>3.0.CO;2-0)
15. Lerch MM, Weidenbach H, Hernandez CA, Predik G, Adler G. 1994 Pancreatic outflow obstruction as the critical event for human gall stone induced pancreatitis. *Gut* **35**, 1501–1503. (doi:10.1136/gut.35.10.1501)
16. Venglovecz V, Rakonczay Jr Z, Ozsvari B, Takacs T, Lonovics J, Varro A, Gray MA, Argent BE, Hegyi P. 2008 Effects of bile acids on pancreatic ductal bicarbonate secretion in guinea pig. *Gut* **57**, 1102–1112. (doi:10.1136/gut.2007.134361)
17. Maleth J, Venglovecz V, Razga Z, Tiszlavicz L, Rakonczay Jr Z, Hegyi P. 2011 Non-conjugated chenodeoxycholate induces severe mitochondrial damage and inhibits bicarbonate transport in pancreatic duct cells. *Gut* **60**, 136–138. (doi:10.1136/gut.2009.192153)
18. Schulz S *et al.* 2013 Progressive stages of mitochondrial destruction caused by cell toxic bile salts. *Biochim. Biophys. Acta* **1828**, 2121–2133. (doi:10.1016/j.bbame.2013.05.007)
19. Gerasimenko JV, Flowerdew SE, Voronina SG, Sukhomlin TK, Tepikin AV, Petersen OH, Gerasimenko OV. 2006 Bile acids induce Ca<sup>2+</sup> release from both the endoplasmic reticulum and acidic intracellular calcium stores through activation of inositol triphosphate receptors and ryanodine receptors. *J. Biol. Chem.* **281**, 40 154–40 163. (doi:10.1074/jbc.M606402200)
20. Voronina SG, Barrow SL, Simpson AW, Gerasimenko OV, da Silva Xavier G, Rutter GA, Petersen OH, Tepikin AV. 2010 Dynamic changes in cytosolic and mitochondrial ATP levels in pancreatic acinar cells. *Gastroenterology* **138**, 1976–1987. (doi:10.1053/j.gastro.2010.01.037)
21. Voronina SG, Barrow SL, Gerasimenko OV, Petersen OH, Tepikin AV. 2004 Effects of secretagogues and bile acids on mitochondrial membrane potential of pancreatic acinar cells: comparison of different modes of evaluating DeltaPsm. *J. Biol. Chem.* **279**, 27 327–27 338. (doi:10.1074/jbc.M311698200)
22. Perides G, Laukkarinen JM, Vassileva G, Steer ML. 2010 Biliary acute pancreatitis in mice is mediated by the G-protein-coupled cell surface bile acid receptor Gpbar1. *Gastroenterology* **138**, 715–725. (doi:10.1053/j.gastro.2009.10.052)
23. Katona M, Hegyi P, Kui B, Balla Z, Rakonczay Jr Z, Razga Z, Tiszlavicz L, Maleth J, Venglovecz V. 2016 A novel, protective role of ursodeoxycholate in bile-induced pancreatic ductal injury. *Am. J. Physiol. Gastrointest. Liver Physiol.* **310**, G193–G204.
24. Malo A, Kruger B, Seyhun E, Schafer C, Hoffmann RT, Goke B, Kubisch CH. 2010 Tauroursodeoxycholic acid reduces endoplasmic reticulum stress, trypsin activation, and acinar cell apoptosis while increasing secretion in rat pancreatic acini. *Am. J. Physiol. Gastrointest. Liver Physiol.* **299**, G877–G886. (doi:10.1152/ajpgi.00423.2009)
25. Seyhun E, Malo A, Schafer C, Moskaluk CA, Hoffmann RT, Goke B, Kubisch CH. 2011 Tauroursodeoxycholic acid reduces endoplasmic reticulum stress, acinar cell damage, and systemic inflammation in acute pancreatitis. *Am. J. Physiol. Gastrointest. Liver Physiol.* **301**, G773–G782. (doi:10.1152/ajpgi.00483.2010)
26. Yadav D, Lowenfels AB. 2013 The epidemiology of pancreatitis and pancreatic cancer. *Gastroenterology* **144**, 1252–1261. (doi:10.1053/j.gastro.2013.01.068)
27. Whitcomb DC. 2012 Genetics of alcoholic and nonalcoholic pancreatitis. *Curr. Opin. Gastroenterol.* **28**, 501–506. (doi:10.1097/MOG.0b013e328356e7f3)
28. Criddle DN, Raraty MG, Neoptolemos JP, Tepikin AV, Petersen OH, Sutton R. 2004 Ethanol toxicity in pancreatic acinar cells: mediation by nonoxidative fatty acid metabolites. *Proc. Natl Acad. Sci. USA* **101**, 10 738–10 743. (doi:10.1073/pnas.0403431101)
29. Criddle DN, McLaughlin E, Murphy JA, Petersen OH, Sutton R. 2007 The pancreas misled: signals to pancreatitis. *Pancreatol.* **7**, 436–446. (doi:10.1159/000108960)
30. Criddle DN, Murphy J, Fistetto G, Barrow S, Tepikin AV, Neoptolemos JP, Sutton R, Petersen OH. 2006 Fatty acid ethyl esters cause pancreatic calcium toxicity via inositol triphosphate receptors and loss of ATP synthesis. *Gastroenterology* **130**, 781–793. (doi:10.1053/j.gastro.2005.12.031)
31. Huang W *et al.* 2014 Fatty acid ethyl ester synthase inhibition ameliorates ethanol-induced Ca<sup>2+</sup>-dependent mitochondrial dysfunction and acute pancreatitis. *Gut* **63**, 1313–1324. (doi:10.1136/gutjnl-2012-304058)
32. Yamamoto A *et al.* 2003 Ethanol induces fluid hypersecretion from guinea-pig pancreatic duct cells. *J. Physiol.* **551**, 917–926. (doi:10.1113/jphysiol.2003.048827)
33. Maleth J *et al.* 2015 Alcohol disrupts levels and function of the cystic fibrosis transmembrane conductance regulator to promote development of pancreatitis. *Gastroenterology* **148**, 427–439. (doi:10.1053/j.gastro.2014.11.002)
34. Judak L, Hegyi P, Rakonczay Jr Z, Maleth J, Gray MA, Venglovecz V. 2014 Ethanol and its non-oxidative metabolites profoundly inhibit CFTR function in pancreatic epithelial cells which is prevented by ATP supplementation. *Pflugers Arch.* **466**, 549–562. (doi:10.1007/s00424-013-1333-x)
35. Pallagi P *et al.* 2011 Trypsin reduces pancreatic ductal bicarbonate secretion by inhibiting CFTR Cl<sup>-</sup> channels and luminal anion exchangers. *Gastroenterology* **141**, 2228–2239. (doi:10.1053/j.gastro.2011.08.039)
36. Jin S, Orabi AI, Le T, Javed TA, Sah S, Eisses JF, Bottino R, Molkentin JD, Husain SZ. 2015 Exposure to radiocontrast agents induces pancreatic inflammation by activation of nuclear factor-kappaB, calcium signaling, and calcineurin. *Gastroenterology* **149**, 753–764. (doi:10.1053/j.gastro.2015.05.004)
37. Berridge MJ. 1993 Inositol triphosphate and calcium signalling. *Nature* **361**, 315–325. (doi:10.1038/361315a0)
38. Thorn P, Lawrie AM, Smith PM, Gallacher DV, Petersen OH. 1993 Ca<sup>2+</sup> oscillations in pancreatic acinar cells: spatiotemporal relationships and functional implications. *Cell Calcium* **14**, 746–757. (doi:10.1016/0143-4160(93)90100-K)
39. Petersen OH, Tepikin AV. 2008 Polarized calcium signaling in exocrine gland cells. *Annu. Rev. Physiol.* **70**, 273–299. (doi:10.1146/annurev.physiol.70.113006.100618)
40. Putney Jr JW. 1978 Stimulus-permeability coupling: role of calcium in the receptor regulation of membrane permeability. *Pharmacol. Rev.* **30**, 209–245.
41. Hoth M, Penner R. 1992 Depletion of intracellular calcium stores activates a calcium current in mast cells. *Nature* **355**, 353–356. (doi:10.1038/355353a0)
42. Liou J, Kim ML, Heo WD, Jones JT, Myers JW, Ferrell Jr JE, Meyer T. 2005 STIM is a Ca<sup>2+</sup> sensor essential for Ca<sup>2+</sup>-store-depletion-triggered Ca<sup>2+</sup> influx. *Curr. Biol.* **15**, 1235–1241. (doi:10.1016/j.cub.2005.05.055)
43. Feske S *et al.* 2006 A mutation in Orai1 causes immune deficiency by abrogating CRAC channel function. *Nature* **441**, 179–185. (doi:10.1038/nature04702)

44. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A, Hogan PG. 2006 Orai1 is an essential pore subunit of the CRAC channel. *Nature* **443**, 230–233. (doi:10.1038/nature05122)
45. Lee KP, Yuan JP, Hong JH, So I, Worley PF, Muallem S. 2010 An endoplasmic reticulum/plasma membrane junction: STIM1/Orai1/TRPCs. *FEBS Lett.* **584**, 2022–2027. (doi:10.1016/j.febslet.2009.11.078)
46. Yuan JP, Zeng W, Dorwart MR, Choi YJ, Worley PF, Muallem S. 2009 SOAR and the polybasic STIM1 domains gate and regulate Orai channels. *Nat. Cell Biol.* **11**, 337–343. (doi:10.1038/ncb1842)
47. Yuan JP, Zeng W, Huang GN, Worley PF, Muallem S. 2007 STIM1 heteromultimerizes TRPC channels to determine their function as store-operated channels. *Nat. Cell Biol.* **9**, 636–645. (doi:10.1038/ncb1590)
48. Kim JY, Zeng W, Kiselyov K, Yuan JP, Dehoff MH, Mikoshiba K, Worley PF, Muallem S. 2006 Homer 1 mediates store- and inositol 1,4,5-trisphosphate receptor-dependent translocation and retrieval of TRPC3 to the plasma membrane. *J. Biol. Chem.* **281**, 32 540–32 549. (doi:10.1074/jbc.M602496200)
49. Nilius B, Owsianik G, Voets T, Peters JA. 2007 Transient receptor potential cation channels in disease. *Physiol. Rev.* **87**, 165–217. (doi:10.1152/physrev.00021.2006)
50. Hong JH, Li Q, Kim MS, Shin DM, Feske S, Birnbaumer L, Cheng KT, Ambudkar IS, Muallem S. 2011 Polarized but differential localization and recruitment of STIM1, Orai1 and TRPC channels in secretory cells. *Traffic* **12**, 232–245. (doi:10.1111/j.1600-0854.2010.01138.x)
51. Lur G, Haynes LP, Prior IA, Gerasimenko OV, Feske S, Petersen OH, Burgoyne RD, Tepikin AV. 2009 Ribosome-free terminals of rough ER allow formation of STIM1 puncta and segregation of STIM1 from IP(3) receptors. *Curr. Biol.* **19**, 1648–1653. (doi:10.1016/j.cub.2009.07.072)
52. Ambudkar IS. 2012 Polarization of calcium signaling and fluid secretion in salivary gland cells. *Curr. Med. Chem.* **19**, 5774–5781. (doi:10.2174/092986712804143321)
53. Kim MH, Seo JB, Burnett LA, Hille B, Koh DS. 2013 Characterization of store-operated  $Ca^{2+}$  channels in pancreatic duct epithelia. *Cell Calcium* **54**, 266–275. (doi:10.1016/j.ceca.2013.07.002)
54. Koh DS, Moody MW, Nguyen TD, Hille B. 2000 Regulation of exocytosis by protein kinases and  $Ca^{2+}$  in pancreatic duct epithelial cells. *J. Gen. Physiol.* **116**, 507–520. (doi:10.1085/jgp.116.4.507)
55. Hansford RG, Zorov D. 1998 Role of mitochondrial calcium transport in the control of substrate oxidation. *Mol. Cell. Biochem.* **184**, 359–369. (doi:10.1023/A:1006893903113)
56. Rizzuto R, Simpson AW, Brini M, Pozzan T. 1992 Rapid changes of mitochondrial  $Ca^{2+}$  revealed by specifically targeted recombinant aequorin. *Nature* **358**, 325–327. (doi:10.1038/358325a0)
57. Csordas G, Thomas AP, Hajnoczky G. 1999 Quasi-synaptic calcium signal transmission between endoplasmic reticulum and mitochondria. *EMBO J.* **18**, 96–108. (doi:10.1093/emboj/18.1.96)
58. Rizzuto R, Duchen MR, Pozzan T. 2004 Flirting in little space: the ER/mitochondria  $Ca^{2+}$  liaison. *Sci. STKE* **2004**, re1. (doi:10.1126/stke.2152004re1)
59. De Stefani D, Raffaello A, Teardo E, Szabo I, Rizzuto R. 2011 A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. *Nature* **476**, 336–340. (doi:10.1038/nature10230)
60. Baughman JM *et al.* 2011 Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. *Nature* **476**, 341–345. (doi:10.1038/nature10234)
61. Palty R *et al.* 2010 NCLX is an essential component of mitochondrial  $Na^{+}/Ca^{2+}$  exchange. *Proc. Natl Acad. Sci. USA* **107**, 436–441. (doi:10.1073/pnas.0908099107)
62. Tait SW, Green DR. 2010 Mitochondria and cell death: outer membrane permeabilization and beyond. *Nat. Rev. Mol. Cell Biol.* **11**, 621–632. (doi:10.1038/nrm2952)
63. Halestrap AP. 2009 What is the mitochondrial permeability transition pore? *J. Mol. Cell. Cardiol.* **46**, 821–831. (doi:10.1016/j.yjmcc.2009.02.021)
64. Golstein P, Kroemer G. 2007 Cell death by necrosis: towards a molecular definition. *Trends Biochem. Sci.* **32**, 37–43. (doi:10.1016/j.tibs.2006.11.001)
65. Elrod JW *et al.* 2010 Cyclophilin D controls mitochondrial pore-dependent  $Ca^{2+}$  exchange, metabolic flexibility, and propensity for heart failure in mice. *J. Clin. Invest.* **120**, 3680–3687. (doi:10.1172/JCI43171)
66. De Marchi E, Bonora M, Giorgi C, Pinton P. 2014 The mitochondrial permeability transition pore is a dispensable element for mitochondrial calcium efflux. *Cell Calcium* **56**, 1–13. (doi:10.1016/j.ceca.2014.03.004)
67. Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. 2000 Reactive oxygen species (ROS)-induced ROS release: a new phenomenon accompanying induction of the mitochondrial permeability transition in cardiac myocytes. *J. Exp. Med.* **192**, 1001–1014. (doi:10.1084/jem.192.7.1001)
68. Kwong JQ, Molkentin JD. 2015 Physiological and pathological roles of the mitochondrial permeability transition pore in the heart. *Cell Metab.* **21**, 206–214. (doi:10.1016/j.cmet.2014.12.001)
69. Crompton M, Virji S, Ward JM. 1998 Cyclophilin-D binds strongly to complexes of the voltage-dependent anion channel and the adenine nucleotide translocase to form the permeability transition pore. *Eur. J. Biochem.* **258**, 729–735. (doi:10.1046/j.1432-1327.1998.2580729.x)
70. Halestrap AP, Richardson AP. 2015 The mitochondrial permeability transition: a current perspective on its identity and role in ischaemia/reperfusion injury. *J. Mol. Cell. Cardiol.* **78**, 129–141. (doi:10.1016/j.yjmcc.2014.08.018)
71. Kokoszka JE, Waymire KG, Levy SE, Sligh JE, Cai J, Jones DP, MacGregor GR, Wallace DC. 2004 The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. *Nature* **427**, 461–465. (doi:10.1038/nature02229)
72. Baines CP *et al.* 2005 Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. *Nature* **434**, 658–662. (doi:10.1038/nature03434)
73. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. 2005 Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. *Nature* **434**, 652–658. (doi:10.1038/nature03317)
74. Karch J *et al.* 2013 Bax and Bak function as the outer membrane component of the mitochondrial permeability pore in regulating necrotic cell death in mice. *Elife* **2**, e00772. (doi:10.7554/eLife.00772)
75. Giorgio V, Bisetto E, Soriano ME, Dabbeni-Sala F, Basso E, Petronilli V, Forte MA, Bernardi P, Lippe G. 2009 Cyclophilin D modulates mitochondrial FO1-ATP synthase by interacting with the lateral stalk of the complex. *J. Biol. Chem.* **284**, 33 982–33 988. (doi:10.1074/jbc.M109.020115)
76. Gutierrez-Aguilar M, Douglas DL, Gibson AK, Domeier TL, Molkentin JD, Baines CP. 2014 Genetic manipulation of the cardiac mitochondrial phosphate carrier does not affect permeability transition. *J. Mol. Cell. Cardiol.* **72**, 316–325. (doi:10.1016/j.yjmcc.2014.04.008)
77. Mukherjee R *et al.* In press. Mechanism of mitochondrial permeability transition pore induction and damage in the pancreas: inhibition prevents acute pancreatitis by protecting production of ATP. *Gut* (doi:10.1136/gutjnl-2014-308553)
78. Toescu EC, O'Neill SC, Petersen OH, Eisner DA. 1992 Caffeine inhibits the agonist-evoked cytosolic  $Ca^{2+}$  signal in mouse pancreatic acinar cells by blocking inositol trisphosphate production. *J. Biol. Chem.* **267**, 23 467–23 470.
79. Wakui M, Osipchuk YV, Petersen OH. 1990 Receptor-activated cytoplasmic  $Ca^{2+}$  spiking mediated by inositol trisphosphate is due to  $Ca_2(+)$ -induced  $Ca^{2+}$  release. *Cell* **63**, 1025–1032. (doi:10.1016/0092-8674(90)90505-9)
80. Saleem H, Tovey SC, Molinski TF, Taylor CW. 2014 Interactions of antagonists with subtypes of inositol 1,4,5-trisphosphate (IP3) receptor. *Br. J. Pharmacol.* **171**, 3298–3312. (doi:10.1111/bph.12685)
81. Morton C, Klatsky AL, Udaltsova N. 2004 Smoking, coffee, and pancreatitis. *Am. J. Gastroenterol.* **99**, 731–738. (doi:10.1111/j.1572-0241.2004.04143.x)
82. Huang W *et al.* In press. Caffeine protects against experimental acute pancreatitis by inhibition of inositol 1,4,5-trisphosphate receptor-mediated  $Ca^{2+}$  release. *Gut* (doi:10.1136/gutjnl-2015-309363)
83. Kim MS, Hong JH, Li Q, Shin DM, Abramowitz J, Birnbaumer L, Muallem S. 2009 Deletion of TRPC3 in mice reduces store-operated  $Ca^{2+}$  influx and the severity of acute pancreatitis. *Gastroenterology* **137**, 1509–1517. (doi:10.1053/j.gastro.2009.07.042)
84. Kim MS, Lee KP, Yang D, Shin DM, Abramowitz J, Kiyonaka S, Birnbaumer L, Mori Y, Muallem S. 2011 Genetic and pharmacologic inhibition of the  $Ca^{2+}$  influx channel TRPC3 protects secretory epithelia from  $Ca^{2+}$ -dependent toxicity. *Gastroenterology* **140**, 2107–2115. (doi:10.1053/j.gastro.2011.02.052)

85. Gerasimenko JV *et al.* 2013 Ca<sup>2+</sup> release-activated Ca<sup>2+</sup> channel blockade as a potential tool in antipancreatitis therapy. *Proc. Natl Acad. Sci. USA* **110**, 13 186–13 191. (doi:10.1073/pnas.1300910110)
86. Wen L *et al.* 2015 Inhibitors of ORA1 prevent cytosolic calcium-associated injury of human pancreatic acinar cells and acute pancreatitis in 3 mouse models. *Gastroenterology* **149**, 481–492. (doi:10.1053/j.gastro.2015.04.015)
87. Atar D *et al.* 2015 Effect of intravenous TR040303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. *Eur. Heart J.* **36**, 112–119. (doi:10.1093/eurheartj/ehu331)
88. Cung TT *et al.* 2015 Cyclosporine before PCI in patients with acute myocardial infarction. *N. Engl. J. Med.* **373**, 1021–1031. (doi:10.1056/NEJMoa1505489)
89. Monassier L, Ayme-Dietrich E, Aubertin-Kirch G, Pathak A. 2015 Targeting myocardial reperfusion injuries with cyclosporine in the CIRCUS trial: pharmacological reasons for failure. *Fundam. Clin. Pharmacol.* **2**, 191–193. (doi:10.1111/fcp.12177)
90. Coelmont L *et al.* 2010 DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. *PLoS ONE* **5**, e13687. (doi:10.1371/journal.pone.0013687)